Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients

50% Of Older US Patients Untreated

 
• By Andrew McConaghie
  
Roche_Basel
Roche's Evrysdi is third to market in SMA, but is building up a competitive profile to challenge Spinraza and Zolgensma • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category